August 26, 2011
To whom it may concern:

Company Name : TOHO HOLDINGS CO., LTD.
Representative : Norio Hamada /President and Representative Director(Securities Code: 8129 / First Section of Tokyo Stock Exchange)
Contact : Katsuya Kato, Corporate Officer andGeneral Manager of Corporate Communications Officeand Corporate Planning Office(TEL: 03-5259-9520)

Notice Regarding the Acquisition of Shares by a Subsidiary

As announced in the Notice Regarding the Commencement of Consultations for the Establishment of a Business
Alliance between Toho Pharmaceutical Co., Ltd. and Koizumi Yakuhin Co., Ltd., released on March 10 this year,TOHO HOLDINGS CO., LTD. (hereinafter “TOHO HOLDINGS”) and IWAKI & CO., LTD. (hereinafter“IWAKI”) have promoted concrete consultations concerning a business alliance with regard to a reagent business.
TOHO HOLDINGS is pleased to announce that, as a result of the above consultations, both companies haveconcluded today an agreement on the transfer of stock and, consequently, TOHO PHARMACEUTICAL CO.,LTD., (hereinafter “TOHO PHARMACEUTICAL”), a consolidated subsidiary of TOHO HOLDINGS will
acquire all the outstanding shares of Koizumi Yakuhin Co., Ltd. (hereinafter “Koizumi Yakuhin”), a consolidated
subsidiary of IWAKI as of October 1, 2011 (effective date).

1. Reason for the Stock transfer
TOHO PHARMACEUTICAL is engaged in the sales of prescription pharmaceuticals, reagents and medical
devices throughout the 47 prefectures of Japan as a pharmaceutical wholesaling company of the Kyoso Mirai
Group, with TOHO HOLDINGS as its core company.
On the other hand, Koizumi Yakuhin was originally founded as Koizumi Pharmacy in April 1892. Since April
1966, the Company has been deploying aggressive sales activities as a wholesaling company for reagents aspart of the IWAKI Group in Tohoku district, mainly in Miyagi prefecture.
Recently, both TOHO HOLDINGS and IWAKI did specific discussions for a business tie-up between
TOHO PHARMACEUTICAL and Koizumi Yakuhin under the common understanding that it is essential torespond to customer needs through the improvement of specialization in various pharmaceutical business fields
and enhancement of the functions of medical delivery systems by utilizing management resources of bothcompanies for the wholesaling business of clinical reagents in Tohoku district.

2. Outlines of the Parties・IWAKI & CO., LTD.

(Securities Code: 8095 / First Section of Tokyo Stock Exchange)

Business contents

Sales of pharmaceuticals, raw materials for medicines and cosmetics, chemicals,
food products, and so forth.

Establishment

September 20, 1941

Principal place of business

4-8-2, Nihonbashi Honcho, Chuo Ward, Tokyo

Corporate representative

Osamu Iwaki / President and CEO

Capital2.572 billion Yen

Net sales

50,412 million yen (Consolidated financial year ended November 31, 2010)

・Koizumi Yakuhin Co., Ltd. (Subsidiary of IWAKI)
Business contents

Sales of in vitro diagnostic reagents, medical equipment and pharmaceuticalproducts.

Establishment

November 30, 1948

Principal place of business

3-4-7, Oroshi-machi, Wakabayashi Ward, Sendai City, Miyagi

Corporate representative

Masahiko Kato / President

Capital24 million yen

Net sales

1,548 million yen (Financial year ended November 31, 2010)

・TOHO HOLDINGS CO., LTD. (Securities Code: 8129 / First Section of Tokyo Stock Exchange)
Business contents

Holding company’s function, namely control and management ofoperating companies

Establishment

September 17, 1948

Principal place of business

5-2-1 Daizawa, Setagaya Ward, Tokyo

Corporate representative

Norio Hamada / President and Representative Director

Capital

10,649 million yen

Net sales

1,059,612 million yen (Consolidated financial year ended March 31, 2011)

・TOHO PHARMACEUTICAL CO., LTD. (Subsidiary of TOHO HOLDINGS)
Business contents

Wholesales of pharmaceuticals, over-the-counter (OTC) pharmaceuticals,reagents, medical equipment and others.

Establishment

November 4, 2008

Principal place of business

5-2-1 Daizawa, Setagaya Ward, Tokyo

Corporate representative

Hiroyuki Kono / President and Representative DirectorCapital

300 million yen

Net sales

1,005,498 million yen (Financial year ended March 31, 2011)

3. Schedule
August 26, 2011

Conclusion of agreement on the stock transfer

October 1, 2011

Stock transfer date（effective date）

4. Impact on business performance
Impact on future the company’s consolidated operating results are considered insignificant.